CLINICAL TRIALS PROFILE FOR DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

All Clinical Trials for dextrose; magnesium acetate; potassium acetate; sodium chloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00212043 ↗	Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma	Completed	Eli Lilly and Company	Phase 2	2000-07-01	Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer
NCT00212043 ↗	Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma	Completed	National University Hospital, Singapore	Phase 2	2000-07-01	Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer
NCT02294656 ↗	Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide	Completed	Genentech, Inc.	Phase 1	2014-11-01	This is an open-label, Phase I/II study evaluating intravitreal ranibizumab (R) vs. intravitreal Triesence (triamcinolone acetonide) (T) in subjects with acute pseudophakic cystoid macular edema (CME). Twenty consented patients with acute CME after phacoemulsification cataract surgery with posterior chamber intraocular lens implantation (PE/PCIOL) will be randomized 1:1 to treatment with R or T. R patients will receive three monthly R injections, followed by PRN dosing. T patients will receive PRN injections every 3 months. Clinical CME is defined as clinically evident CME, with visual acuity (VA) typically in the 20/40 to 20/200 range. Re-treatment criteria will include clinically evident worsening of CME, combined with any of the following: - Any increase in spectral domain ocular coherence tomography (OCT) central macular thickness (CMT) - Any observable fluid on OCT - Any qualitatively increased perifoveal leakage/pooling on fluorescein angiography (FA). Patients will be followed monthly through 12 months.
NCT02294656 ↗	Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide	Completed	Soll Eye	Phase 1	2014-11-01	This is an open-label, Phase I/II study evaluating intravitreal ranibizumab (R) vs. intravitreal Triesence (triamcinolone acetonide) (T) in subjects with acute pseudophakic cystoid macular edema (CME). Twenty consented patients with acute CME after phacoemulsification cataract surgery with posterior chamber intraocular lens implantation (PE/PCIOL) will be randomized 1:1 to treatment with R or T. R patients will receive three monthly R injections, followed by PRN dosing. T patients will receive PRN injections every 3 months. Clinical CME is defined as clinically evident CME, with visual acuity (VA) typically in the 20/40 to 20/200 range. Re-treatment criteria will include clinically evident worsening of CME, combined with any of the following: - Any increase in spectral domain ocular coherence tomography (OCT) central macular thickness (CMT) - Any observable fluid on OCT - Any qualitatively increased perifoveal leakage/pooling on fluorescein angiography (FA). Patients will be followed monthly through 12 months.
NCT02798757 ↗	Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy	Completed	University of Ioannina	Phase 4	2016-06-01	This is a phase IV study that will explore the mechanisms of action of a drug (dapagliflozin) that is already commercially available in the country where the study will be conducted (Greece). The drug will be used according to its approved clinical indications (as add-on treatment in patients failed to achieve glycemic targets on metformin monotherapy) and in the approved posology (10 mg/day). Additionally, although there is limited data on the coadministration of dapagliflozin with thiazides, the excellent safety profile of the drug even when it is used in combination with drugs that induce significant volume depletion (such as loop diuretics) suggests that, in properly selected patients, the possibility of important adverse events during the coadministration of dapagliflozin with chlorthalidone is very low. All patients will give written informed consent prior to their enrollment in the study. The study protocol will be approved by the scientific committee of the University Hospital of Ioannina.
NCT03299452 ↗	Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor	Unknown status	Alphacait, LLC	Phase 2	2017-01-01	This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor.

Clinical Trial Conditions for dextrose; magnesium acetate; potassium acetate; sodium chloride

Condition Name

Condition Name for dextrose; magnesium acetate; potassium acetate; sodium chloride
Intervention	Trials
CYSTOID MACULAR EDEMA	1
Diabetes	1
Metastatic Cancer	1
Neuromuscular Scoliosis	1

Condition MeSH

Condition MeSH for dextrose; magnesium acetate; potassium acetate; sodium chloride
Intervention	Trials
Neoplasm Metastasis	1
Macular Edema	1
Edema	1
Carcinoma, Non-Small-Cell Lung	1

Clinical Trial Locations for dextrose; magnesium acetate; potassium acetate; sodium chloride

Trials by Country

Trials by Country for dextrose; magnesium acetate; potassium acetate; sodium chloride
Location	Trials
China	1
Greece	1
United States	1
Finland	1

Trials by US State

Trials by US State for dextrose; magnesium acetate; potassium acetate; sodium chloride
Location	Trials
Pennsylvania	1

Clinical Trial Progress for dextrose; magnesium acetate; potassium acetate; sodium chloride

Clinical Trial Phase

Clinical Trial Phase for dextrose; magnesium acetate; potassium acetate; sodium chloride
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for dextrose; magnesium acetate; potassium acetate; sodium chloride
Clinical Trial Phase	Trials
Completed	3
RECRUITING	1
Unknown status	1

Clinical Trial Sponsors for dextrose; magnesium acetate; potassium acetate; sodium chloride

Sponsor Name

Sponsor Name for dextrose; magnesium acetate; potassium acetate; sodium chloride
Sponsor	Trials
National University Hospital, Singapore	1
Genentech, Inc.	1
Soll Eye	1

Sponsor Type

Sponsor Type for dextrose; magnesium acetate; potassium acetate; sodium chloride
Sponsor	Trials
Other	6
Industry	2
OTHER_GOV	1

Clinical Trials Update, Market Analysis, and Projection for Electrolyte Solutions: Dextrose, Magnesium Acetate, Potassium Acetate, and Sodium Chloride

Last updated: November 13, 2025

Introduction

Electrolyte solutions are cornerstone therapies in clinical settings, particularly in managing dehydration, electrolyte imbalances, and parenteral nutrition. Among these, formulations including dextrose, magnesium acetate, potassium acetate, and sodium chloride dominate hospitals worldwide. Their market relevance is derived from ongoing clinical research, clinical applications, and technological advancements that influence demand dynamics.

This report provides a comprehensive update on clinical trials, analyses market trends, and projects future growth for these key electrolyte compounds.

---

Clinical Trials Landscape for Electrolyte Solutions

Current Clinical Research Directions

Recent years have seen a surge in clinical trials focusing on electrolyte therapies, primarily to optimize safety profiles, enhance delivery methods, and evaluate efficacy across various patient populations.

• Dextrose is extensively studied as a component of parenteral nutrition (PN), with trials exploring its role in metabolic management, particularly in diabetic and critically ill patients. Its use extends into glucose control protocols and its integration with other nutrients to improve patient outcomes [1].

• Magnesium Acetate trials primarily target its efficacy in correcting hypomagnesemia, especially in cardiac and neurological disorders. Recent trials also focus on its neuroprotective properties post-stroke or traumatic brain injury, emphasizing neurovascular mechanisms [2].

• Potassium Acetate remains central in managing potassium deficits. Trials are evaluating its safety in high-risk populations, including pediatric and renal failure patients, and its integration into total parenteral nutrition (TPN) solutions [3].

• Sodium Chloride studies examine its use in fluid resuscitation, treatment of hyponatremia, and electrolyte correction protocols. Innovations include formulations aimed at reducing phlebitis and tissue injury during administration [4].

Emerging Trends

Key trends in ongoing research include:

• Personalized electrolyte therapy: Trials are increasingly stratifying interventions based on genetic, metabolic, and disease-specific factors to tailor electrolyte management.

• Novel delivery systems: Development of slow-release or targeted delivery formulations to reduce risk of electrolyte imbalance and adverse effects.

• Safety and toxicity assessment: Focused research into hypernatremia, hypermagnesemia, and other electrolyte excesses, with clinical trials designed to optimize dosing and minimize complications.

Regulatory Considerations

The increasing volume of clinical data has led to accelerated FDA review processes for electrolyte formulations, especially in critical care settings. Recent approvals for electrolyte solutions with improved safety profiles reflect this trend [5].

---

Market Analysis

Market Size and Growth Drivers

The global electrolyte solutions market was valued at approximately USD 8 billion in 2022 and is projected to grow at a compounded annual growth rate (CAGR) of nearly 6% through 2030 [6].

Key growth drivers include:

• Expanding healthcare infrastructure in emerging markets, leading to increased demand for electrolyte therapy in hospitals, clinics, and emergency services.

• Rising prevalence of chronic diseases, including diabetes, renal failure, and cardiovascular conditions, necessitating regular electrolyte management.

• Growth in surgical procedures and critical care admissions, particularly during and post-pandemic periods, augment the need for parenteral and intravenous electrolyte solutions.

• Technological innovations leading to safer, more efficient formulations, and alternative delivery mechanisms.

Market Segmentation

• By Product Type:

  • Dextrose solutions: Largest segment due to carbohydrate replenishment needs.

  • Magnesium-based formulations: Growing demand in neuroprotective therapies.

  • Potassium solutions: Critical in electrolyte repletion protocols.

  • Sodium chloride solutions: Ubiquitous in resuscitative and hydration therapies.

• By Application:

  • Hospitals (ICU, surgical units)

  • Emergency services

  • Ambulatory care

  • Parenteral nutrition products

• By Region:

  • North America: Market leader, driven by high healthcare expenditure and advanced medical infrastructure.

  • Europe: Significant contributions from aging populations and chronic disease prevalence.

  • Asia-Pacific: Fastest-growing segment, fueled by expanding healthcare access and infrastructure development.

  • Rest of the World: Emerging markets witnessing increased adoption.

Competitive Landscape

Major players include Baxter International, Fresenius Kabi, B. Braun Melsungen, and Pfizer, with a focus on expanding product portfolios and integrating digital health solutions for monitoring electrolyte balance [7].

---

Market Projections

Forecast Overview

Considering current trends, clinical research momentum, and expanding healthcare infrastructure, the electrolyte solutions market is expected to surpass USD 13 billion by 2030.

Factors Influencing Market Trajectory

• Innovation in formulations: Use of more stable and customizable electrolyte complexes can increase clinical adoption.

• Regulatory approvals: Streamlined processes for new formulations will catalyze market expansion.

• Global health initiatives: Increased emphasis on IV therapy standardization in developing economies.

• COVID-19 Pandemic Impact: While initially disrupting supply chains, the pandemic underscored the importance of critical care electrolytes, accelerating demand in intensive therapy.

Challenges

• Supply chain disruptions: Shortages in raw materials and manufacturing disruptions can hinder growth.

• Regulatory hurdles: Strict approval processes for new formulations may delay market entry.

• Competition from oral therapies: In less severe cases, oral electrolyte solutions pose competition to injectable forms.

---

Key Takeaways

• Clinical research intensity remains high in electrolyte solutions, emphasizing safety, efficacy, and personalized delivery methods. Innovations in formulations and targeted therapies are expected to enhance clinical outcomes.

• Market growth is robust, driven by aging populations, rising chronic disease burden, and technological advances in electrolyte therapy.

• Emerging regions, particularly Asia-Pacific, exhibit the fastest market growth, highlighting opportunities for expansion.

• Regulatory pathways are becoming more streamlined, but supply chain stability remains critical to capitalize on market demand.

• Players investing in R&D and manufacturing flexibility will likely lead market share gains amid evolving healthcare needs.

---

FAQs

Q1: How are clinical trials shaping the future of electrolyte solutions?
A1: Clinical trials inform safety profiles, dosing guidelines, and delivery methods, enabling personalized therapy and improving outcomes. Emerging research on targeted delivery and neuroprotective effects particularly guides product innovation.

Q2: What factors are driving growth in the electrolyte solutions market?
A2: Technological innovations, increased healthcare infrastructure, rising chronic disease prevalence, and expanding critical care needs drive growth, especially in emerging markets.

Q3: Which region offers the most growth opportunities?
A3: Asia-Pacific is the fastest-growing region due to expanding healthcare access, government initiatives, and increasing disease burden.

Q4: What are the main challenges facing electrolyte solution manufacturers?
A4: Supply chain disruptions, regulatory hurdles, and competition from oral electrolyte solutions pose significant challenges.

Q5: How might upcoming regulatory changes impact the market?
A5: Streamlined approval processes for safer, innovative formulations could accelerate market entry, while stringent safety standards may require additional R&D investments.

---

Conclusion

Electrolyte solutions encompassing dextrose, magnesium acetate, potassium acetate, and sodium chloride are integral to contemporary healthcare. With ongoing clinical trials paving the way for safer, more effective formulations and a burgeoning global market, stakeholders must navigate challenges while harnessing emerging opportunities. Strategic R&D, regional expansion, and regulatory agility will be pivotal in shaping future growth trajectories.

---

Sources

[1] ClinicalTrials.gov. "Dextrose in Clinical Trials."
[2] Neurocritical Care Society. "Magnesium's Neuroprotective Role."
[3] Parenteral Nutrition Society. "Potassium Supplementation Guidelines."
[4] Journal of Infusion Nursing. "Sodium chloride formulations in IV therapy."
[5] FDA Regulatory Approvals. "Electrolyte Solutions."
[6] MarketsandMarkets. "Electrolyte Solutions Market Forecast."
[7] IQVIA. "Market Share and Competitive Landscape in IV Solutions."